 Glucuronosyltransferase
"Glucuronosyltransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of enzymes accepting a wide range of substrates, including phenols, alcohols, amines, and fatty acids. They function as drug-metabolizing enzymes that catalyze the conjugation of UDPglucuronic acid to a variety of endogenous and exogenous compounds. EC 2.4.1.17.
| Descriptor ID |
D014453
|
| MeSH Number(s) |
D08.811.913.400.450.480
|
| Concept/Terms |
Glucuronosyltransferase- Glucuronosyltransferase
- Glucuronyltransferase
- UDP Glucuronyl Transferase
- Glucuronyl Transferase, UDP
- Transferase, UDP Glucuronyl
- Glucuronic Transferase
- Transferase, Glucuronic
- UDP Glucuronosyltransferase
- Glucuronosyltransferase, UDP
7-Hydroxycoumarin UDP Glucuronyltransferase- 7-Hydroxycoumarin UDP Glucuronyltransferase
- 7 Hydroxycoumarin UDP Glucuronyltransferase
- Glucuronyltransferase, 7-Hydroxycoumarin UDP
- UDP Glucuronyltransferase, 7-Hydroxycoumarin
|
Below are MeSH descriptors whose meaning is more general than "Glucuronosyltransferase".
Below are MeSH descriptors whose meaning is more specific than "Glucuronosyltransferase".
This graph shows the total number of publications written about "Glucuronosyltransferase" by people in this website by year, and whether "Glucuronosyltransferase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 0 | 1 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 1 | 0 | 1 | | 1985 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1997 | 0 | 2 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 1 | 2 | | 2002 | 5 | 1 | 6 | | 2003 | 4 | 3 | 7 | | 2004 | 5 | 0 | 5 | | 2005 | 6 | 1 | 7 | | 2006 | 6 | 1 | 7 | | 2007 | 7 | 1 | 8 | | 2008 | 5 | 0 | 5 | | 2009 | 0 | 2 | 2 | | 2010 | 5 | 2 | 7 | | 2011 | 5 | 1 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 4 | 0 | 4 | | 2015 | 3 | 2 | 5 | | 2016 | 2 | 0 | 2 | | 2019 | 2 | 1 | 3 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucuronosyltransferase" by people in Profiles.
-
Karas S, Etheridge AS, Nickerson DA, Cox NJ, Mohlke KL, Cecchin E, Toffoli G, Mathijssen RHJ, Forrest A, Bies RR, Innocenti F. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. Br J Cancer. 2022 03; 126(4):640-651.
-
Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MC. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
-
Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
-
Gan L, Ji J, Wang L, Li QY, Zhang CF, Wang CZ, Yuan CS. Identification of the metabolites in normal and AA rat plasma, urine and feces after oral administration of Daphne genkwa flavonoids by LC-Q-TOF-MS spectrometry. J Pharm Biomed Anal. 2020 Jan 05; 177:112856.
-
Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
-
Zhang L, Huang H, Wang H, Chen J, Du G, Kang Z. Rapid evolution of hyaluronan synthase to improve hyaluronan production and molecular mass in Bacillus subtilis. Biotechnol Lett. 2016 Dec; 38(12):2103-2108.
-
Toffoli G, Sharma MR, Marangon E, Posocco B, Gray E, Mai Q, Buonadonna A, Polite BN, Miolo G, Tabaro G, Innocenti F. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):918-924.
-
Wang X, Wang H, Shen B, Overholser BR, Cooper BR, Lu Y, Tang H, Zhou C, Sun X, Zhong L, Favus MJ, Decker BS, Liu W, Peng Z. 1-Alpha, 25-dihydroxyvitamin D3 alters the pharmacokinetics of mycophenolic acid in renal transplant recipients by regulating two extrahepatic UDP-glucuronosyltransferases 1A8 and 1A10. Transl Res. 2016 12; 178:54-62.e6.
-
Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 Apr; 99(4):363-9.
-
Qin J, Kilkus J, Dawson G. The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. Biochim Biophys Acta. 2016 Feb; 1861(2):78-90.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|